Literature DB >> 24714930

[Immune reconstitution inflammatory syndrome after cessation of immunosuppressive therapy].

B Ehrenstein1.   

Abstract

Entities:  

Mesh：

Substances：

Year:  2014        PMID： 24714930     DOI： 10.1007/s00393-014-1386-z

Source DB:  PubMed          Journal:  Z Rheumatol        ISSN： 0340-1855            Impact factor:   1.372


× No keyword cloud information.
  10 in total

Review 1.  Immune reconstitution inflammatory syndrome in patients starting antiretroviral therapy for HIV infection: a systematic review and meta-analysis.

Authors:  Monika Müller; Simon Wandel; Robert Colebunders; Suzanna Attia; Hansjakob Furrer; Matthias Egger
Journal:  Lancet Infect Dis       Date:  2010-04       Impact factor: 25.071

2.  Paradoxical response to antituberculous therapy in infliximab-treated patients with disseminated tuberculosis.

Authors:  Carolina Garcia Vidal; Serena Rodríguez Fernández; Javier Martínez Lacasa; Miquel Salavert; Rafael Vidal; Monica Rodríguez Carballeira; Javier Garau
Journal:  Clin Infect Dis       Date:  2005-02-04       Impact factor: 9.079

3.  Immune reconstitution inflammatory syndrome in natalizumab-associated PML.

Authors:  I L Tan; J C McArthur; D B Clifford; E O Major; A Nath
Journal:  Neurology       Date:  2011-08-10       Impact factor: 9.910

4.  Paradoxical immune reconstitution inflammatory syndrome associated with rituximab-containing regimen in a patient with lymphoma.

Authors:  Jonathan Canaani; Sharon Amit; Jonathan Ben-Ezra; Mehrzad Cohen Pour; Nadav Sarid; Hedva Lerman; Chava Perry; Aaron Polliack; Elizabeth Naparstek; Yair Herishanu
Journal:  J Clin Oncol       Date:  2013-02-25       Impact factor: 44.544

5.  Maraviroc and JC virus-associated immune reconstitution inflammatory syndrome.

Authors:  Paul S Giacomini; Ayal Rozenberg; Imke Metz; David Araujo; Nathalie Arbour; Amit Bar-Or
Journal:  N Engl J Med       Date:  2014-01-30       Impact factor: 91.245

6.  Tuberculosis associated with infliximab, a tumor necrosis factor alpha-neutralizing agent.

Authors:  J Keane; S Gershon; R P Wise; E Mirabile-Levens; J Kasznica; W D Schwieterman; J N Siegel; M M Braun
Journal:  N Engl J Med       Date:  2001-10-11       Impact factor: 91.245

Review 7.  Immunorestitution disease involving the innate and adaptive response.

Authors:  V C Cheng; K Y Yuen; W M Chan; S S Wong; E S Ma; R M Chan
Journal:  Clin Infect Dis       Date:  2000-06-20       Impact factor: 9.079

8.  Risk factor analyses for immune reconstitution inflammatory syndrome in a randomized study of early vs. deferred ART during an opportunistic infection.

Authors:  Philip M Grant; Lauren Komarow; Janet Andersen; Irini Sereti; Savita Pahwa; Michael M Lederman; Joseph Eron; Ian Sanne; William Powderly; Evelyn Hogg; Carol Suckow; Andrew Zolopa
Journal:  PLoS One       Date:  2010-07-01       Impact factor: 3.240

9.  Impairment of JCV-specific T-cell response by corticotherapy: effect on PML-IRIS management?

Authors:  Caroline Antoniol; Samantha Jilek; Myriam Schluep; Noëlle Mercier; Mathieu Canales; Géraldine Le Goff; Claudia Campiche; Giuseppe Pantaleo; Renaud A Du Pasquier
Journal:  Neurology       Date:  2012-11-21       Impact factor: 9.910

10.  Treatment benefit or survival of the fittest: what drives the time-dependent decrease in serious infection rates under TNF inhibition and what does this imply for the individual patient?

Authors:  A Strangfeld; M Eveslage; M Schneider; H J Bergerhausen; T Klopsch; A Zink; J Listing
Journal:  Ann Rheum Dis       Date:  2011-07-25       Impact factor: 19.103
  10 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.